News Sentiment

CORT sentiment intelligence

Corcept Therapeutics Incorporated news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 90.52 Week of 17 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-1.5% over one week, +13.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Corcept Sets July 29 Results Call for 5 p.m. Eastern

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -1.5% Price digesting
Trend fit Trend active 13.3% over four weeks
Fair value 83.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 33
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 8
simplywall.st 7
Motley Fool 3
Investing.com 3
Simply Wall Street 3
TradingView 3
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 17
Regulatory and legal 3
Guidance 2
Balance sheet 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Finviz Direct company coverage

CORT - Corcept Therapeutics Inc Options

This article provides a detailed financial overview of Corcept Therapeutics Inc. (CORT), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider and institution

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 19:11
Source
Finviz
Stock Titan Direct company coverage

If You Invested $1,000 in Corcept Therapeutics Inc (CORT)

This article analyzes the historical performance of an investment in Corcept Therapeutics Inc (CORT). It details how a $1,000 investment would have grown over 1, 5, and 10 years, showcasing significant returns. The article also provides a comprehensive overview of Corcept Therape

Tone
Positive 76/100
Event
Market update
Published
04 Jul 2026 05:09
Source
Stock Titan
Simply Wall Street Direct company coverage

Is Corcept Therapeutics (CORT) Undervalued On Its Russell Index Removal?

Corcept Therapeutics (CORT) was removed from the Russell 1000 Defensive and Growth-Defensive Indices, prompting questions about its valuation despite strong recent share price momentum. While a prominent narrative suggests the stock is 1% overvalued at $88 due to expected revenue

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 16:10
Source
Simply Wall Street
Finviz Direct company coverage

CORT - Corcept Therapeutics Inc Volatility & Greeks

This article provides a detailed financial overview of Corcept Therapeutics Inc (CORT), including its volatility, key financial ratios, performance metrics, and insider/institutional ownership data. It presents a snapshot of the company's market cap, earnings per share, sales gro

Tone
Positive 63/100
Event
Earnings
Published
02 Jul 2026 02:10
Source
Finviz
TradingView Direct company coverage

Price to sales forward of Corcept Therapeutics Incorporated – NASDAQ:CORT

This article provides the forward price-to-sales ratio for Corcept Therapeutics Incorporated (NASDAQ: CORT). It primarily consists of metadata and navigation elements from the TradingView platform, where this financial data point is located. The core content is the mention of the

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 01:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Corcept Therapeutics Incorporated – NASDAQ:CORT

This article focuses on the enterprise value to revenue forward for Corcept Therapeutics Incorporated (NASDAQ: CORT). It presents financial data for the company within the context of the pharmaceuticals industry on TradingView. The page provides a snapshot of CORT's financials an

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 17:39
Source
TradingView
MSN Direct company coverage

Corcept sinks after FDA rejects drug to treat hypertension

The article states that Corcept's stock sank after the FDA rejected its drug for hypertension, which was a significant setback for the company. There is no further content provided to elaborate on the details of the rejection or its potential impact.

Tone
Negative 28/100
Event
Market update
Published
30 Jun 2026 03:10
Source
MSN
marketscreener.com Direct company coverage

Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Defensive Index

Corcept Therapeutics Incorporated (NasdaqCM:CORT) has been removed from the Russell 1000 Defensive Index. This news follows a series of recent announcements for the company, including the resubmission of its NDA for a Cushing Syndrome treatment and several insider share sales. De

Tone
Negative 39/100
Event
Market update
Published
29 Jun 2026 18:10
Source
marketscreener.com
Cushing's Disease News Direct company coverage

Corcept gives FDA new relacorilant data in resubmitted application

Corcept Therapeutics has resubmitted its application to the FDA for relacorilant, a treatment for endogenous Cushing's syndrome, including new data analyses requested by the agency. The resubmission provides additional evidence from Phase 3 trials (GRACE and GRADIENT) demonstrati

Tone
Positive 75/100
Event
Market update
Published
26 Jun 2026 16:11
Source
Cushing's Disease News